Evidence map›Paper›PMID 41340485›Full record

ArticleThe Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology2026

A novel mineralocorticoid receptor blocker, CS-3150, improves insulin resistance and reduces inflammation in db/db mice.

Oyunbileg Bavuu, Daiju Fukuda, Uugantsetseg Munkhjargal, Byambasuren Ganbaatar, Tomoya Hara, Shusuke Yagi, Takeshi Soeki, Masataka Sata

Abstract read
In one paragraph

Article in The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Oyunbileg BavuuDepartment of Cardiovascular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.
Daiju FukudaDepartment of Cardiovascular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.
Uugantsetseg MunkhjargalDepartment of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima 770-8503, Japan.
Byambasuren GanbaatarDepartment of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima 770-8503, Japan.
Tomoya HaraDepartment of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima 770-8503, Japan.
Shusuke YagiDepartment of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima 770-8503, Japan.
Takeshi SoekiDepartment of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima 770-8503, Japan.
Masataka SataDepartment of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima 770-8503, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aldosterone plays a central role in regulating blood pressure and electrolyte balance, and emerging evidence implicates its involvement in metabolic disorders. This study evaluated the metabolic effects of CS-3150, a novel nonsteroidal and selective mineralocorticoid receptor (MR) antagonist, in genetically obese db/db mice. Mice were administered CS-3150 (3 mg/kg/day) for 8 weeks while maintained on a normal chow diet. Metabolic parameters, tissue morphology, inflammatory gene expression, and insulin signaling-assessed

Indexed as

CS-3150Insulin resistanceMineralocorticoid receptorObesity

Identifiers

PMID41340485
PMCPMC12723417

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.